Technical Analysis for SNSS - Sunesis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 0.95 0.00% 0.00
SNSS closed unchanged on Friday, September 13, 2019, on 27 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical SNSS trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Golden Cross Bullish -3.95%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.95%
Calm After Storm Range Contraction -3.95%
NR7 Range Contraction -3.95%

Older signals for SNSS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Biopharmaceutical Drugs Chemical Compounds Organic Compounds Acute Myeloid Leukemia Myelodysplastic Syndrome Orphan Drugs Treatment Of Acute Myeloid Leukemia Lactams High Risk Myelodysplastic Syndrome
Is SNSS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.255
52 Week Low 0.2
Average Volume 784,422
200-Day Moving Average 0.818
50-Day Moving Average 0.8367
20-Day Moving Average 0.897
10-Day Moving Average 0.9798
Average True Range 0.0766
ADX 19.01
+DI 22.0136
-DI 20.3605
Chandelier Exit (Long, 3 ATRs ) 0.8502
Chandelier Exit (Short, 3 ATRs ) 0.9798
Upper Bollinger Band 1.0865
Lower Bollinger Band 0.7075
Percent B (%b) 0.64
BandWidth 42.251951
MACD Line 0.0497
MACD Signal Line 0.0443
MACD Histogram 0.0055
Fundamentals Value
Market Cap 22.34 Million
Num Shares 23.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.50
Price-to-Sales 24.54
Price-to-Book 0.00
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.03
Resistance 3 (R3) 1.02 0.99 1.01
Resistance 2 (R2) 0.99 0.97 0.99 1.01
Resistance 1 (R1) 0.97 0.95 0.98 0.98 1.01
Pivot Point 0.93 0.93 0.94 0.94 0.93
Support 1 (S1) 0.92 0.91 0.93 0.92 0.89
Support 2 (S2) 0.88 0.90 0.89 0.89
Support 3 (S3) 0.86 0.88 0.89
Support 4 (S4) 0.87